4.6 Article

Interferon-γ expression is an independent prognostic factor in ovarian cancer

Journal

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 191, Issue 5, Pages 1598-1605

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2004.05.007

Keywords

interferon-gamma; ovarian cancer; cancer immunology; chemotherapy

Ask authors/readers for more resources

Background: Epithelial ovarian cancer prognosis is improved by the presence of intratumoral CD3(+) T cells; which are known to produce interferon-gamma. We therefore speculated that interferon-gamma expression in ovarian cancer-infiltrating T-lymphocytes might cause better prognosis. Patients and methods: Reverse transcriptase polymerase chain reaction was performed to measure the expression of interferon-gamma and other related genes in normal ovaries (n = 19) and in ovarian cancer specimens (n = 99). Median follow-up of patients was 5.8 years. Results: Interferon-gamma and CD-3 expression did not significantly differ in normal and malignant tissue. Patients with high levels of interferon-gamma expression had significantly longer progression-free and overall survival. Median time to progression was 10 and 29 months for patients with low and high interferon-gamma expression, respectively (P = .039). Corresponding survival times were 29 and 44 months (P < .032). Application of multivariate Cox regression analysis showed interferon-gamma expression to be an independent prognostic factor for progression-free and overall survival. Conclusion: Elevated interferon-gamma expression correlates with improved clinical outcome in patients with ovarian cancer. (C) 2004 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available